The U.S. Food and Drug Administration granted Fast Track designation for ASC Therapeutics’ ASC618, a second-generation gene therapy of hemophilia A.
The FDA has approved pilocarpine hydrochloride ophthalmic solution 1.25% (Vuity, Allergan, an AbbVie company) to treat presbyopia in adults.
Jazz Pharmaceuticals agreed to divest its Sunosi (solriamfetol) drug to Axsome Therapeutics that includes an upfront payment of $53 million.
Earlier research has shown that several of the same risk factors behind the development of cardiovascular disease also can lead to Alzheimer’s.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.
